Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Mirkin

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Maturitas|December 28, 2014
Qualitative cross-cultural exploration of breast symptoms and impacts associated with hormonal treatments for menopausal symptoms to inform the development of new patient-reported measurement toolsLucy Abraham, Louise Humphrey, Rob Arbuckle, et al.
Journal of Women'S Health (2002)|April 9, 2016
Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 TrialsSebastian Mirkin, JoAnn V Pinkerton, Risa Kagan, et al.
Maturitas|April 3, 2017
A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data reviewJames A Simon, David F Archer, Ginger D Constantine, et al.
Contraception|December 14, 2011
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndromeEllen W Freeman, Uriel Halbreich, Gary S Grubb, et al.
Menopause (New York, N.Y.)|January 30, 2019
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)Rogerio A Lobo, James Liu, Frank Z Stanczyk, et al.
Menopause (New York, N.Y.)|October 28, 2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trialGinger D Constantine, James A Simon, Andrew M Kaunitz, et al.
Menopause (New York, N.Y.)|July 13, 2016
Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trialsJ Christopher Gallagher, Santiago Palacios, Kelly A Ryan, et al.
Maturitas|May 27, 2014
Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement toolsRob Arbuckle, Louise Humphrey, Lucy Abraham, et al.
Menopause (New York, N.Y.)|December 7, 2016
The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophyGinger D Constantine, James A Simon, James H Pickar, et al.
Maturitas|July 23, 2013
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 studySantiago Palacios, Tobie J de Villiers, Fiorenzo De Cicco Nardone, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Maturitas|December 28, 2014
Qualitative cross-cultural exploration of breast symptoms and impacts associated with hormonal treatments for menopausal symptoms to inform the development of new patient-reported measurement toolsLucy Abraham, Louise Humphrey, Rob Arbuckle, et al.
Journal of Women'S Health (2002)|April 9, 2016
Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 TrialsSebastian Mirkin, JoAnn V Pinkerton, Risa Kagan, et al.
Maturitas|April 3, 2017
A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data reviewJames A Simon, David F Archer, Ginger D Constantine, et al.
Contraception|December 14, 2011
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndromeEllen W Freeman, Uriel Halbreich, Gary S Grubb, et al.
Menopause (New York, N.Y.)|January 30, 2019
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)Rogerio A Lobo, James Liu, Frank Z Stanczyk, et al.
Menopause (New York, N.Y.)|October 28, 2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trialGinger D Constantine, James A Simon, Andrew M Kaunitz, et al.
Menopause (New York, N.Y.)|July 13, 2016
Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trialsJ Christopher Gallagher, Santiago Palacios, Kelly A Ryan, et al.
Maturitas|May 27, 2014
Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement toolsRob Arbuckle, Louise Humphrey, Lucy Abraham, et al.
Menopause (New York, N.Y.)|December 7, 2016
The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophyGinger D Constantine, James A Simon, James H Pickar, et al.
Maturitas|July 23, 2013
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 studySantiago Palacios, Tobie J de Villiers, Fiorenzo De Cicco Nardone, et al.
Pageof 11